AstraZeneca plc (LSE:AZN; NYSE:AZN) has disclosed 16 pipeline-building deals this year, including six for assets in Phase II and beyond. (A) Following its acquisition of Amylin Pharmaceuticals Inc., Bristol-Myers Squibb Co. (NYSE:BMY) folded Amylin's diabetes portfolio into its 2007 diabetes deal with AstraZeneca; Source: BCIQ: BioCentury Online Intelligence; company press releases

Partner

Deal type

Lead asset(s)/discovery tech

Lead status

Financials

Date

Bristol-Myers Squibb Co. (NYSE:BMY)

Deal expansion (A)

Diabetes drugs Byetta exenatide and Bydureon exenatide

Mkt

$3.4B cash up front plus $135M for equal governance rights on undisclosed parts of deal

Aug-12

The Medicines Co. (NASDAQ:MDCO)

U.S. co- promotion (Brilinta)

AZ's antiplatelet drug Brilinta ticagrelor; Medicines Co.'s anticoagulant Angiomax/Angiox bivalirudin and antiplatelet agent cangrelor (Ph III)

Mkt

$15M/year for 4 years; up to $5M/year in milestones

Apr-12